Pure Global
NCT06336603

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment
Sun Pharmaceutical Industries Limited·Phase 4·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acne Vulgaris
Drug/Device/Intervention
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Pharmaceutical Industries Limited
Location
Louisville, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Nov 15, 2023
End date
Sep 01, 2024
Enrollment
20 participants
Primary outcome

The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16.

Summary

Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris.
 There is no study assessing Winlevi in combination treatment for acne .Therefore this study
 assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.

ICD-10 classifications
Acne vulgarisAcneAcne, unspecifiedAcné excoriéeOther acne
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06336603
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06336603 through Pure Global AI's free database. This Phase 4 trial is sponsored by Sun Pharmaceutical Industries Limited and is currently Recruitment Completed. The study focuses on Acne Vulgaris. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.